Can a supplement cleanse Athletes' lungs? new trial aims to find out
NCT ID NCT07102680
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests whether a supplement called L Max can improve lung health and athletic performance in healthy adult athletes. About 120 participants will take either L Max or a placebo, wear an Oura ring, do daily breathing tests, and complete performance challenges. The goal is to see if L Max helps with breathing during hard workouts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged 18 to 60 years 2. US-based 3. Committed endurance athlete with cycling, triathlon or running focus 4. Achieves three or more Zone 3+ sessions/week 5. Tracks power and time during training 6. Able to use Oura, spirometry, and training apps 7. Routinely feels pulmonary system/breathing limits athletic performance 8. If diagnosed with exercise induce asthma, able to use inhaler only as rescue and not preventatively. 9. Women of childbearing potential (WOCBP) must agree to use highly effective contraception starting at least 14 days prior to the first dose of L Max or placebo, throughout the study period, and for at least 30 days after the last dose of study product. Highly effective methods include the following: abstinence, oral contraceptives, contraceptive injections, intrauterine device, double barrier method (Diaphragm or condom + spermicidal cream) contraceptive patch, or male partner sterilization. Women who are postmenopausal (at least 12 months of spontaneous amenorrhea without an alternative medical cause) or surgically sterile (e.g. hysterectomy, salpingectomy, bilateral oophorectomy, or bilateral tubal ligation) are not considered of childbearing potential. 10. Willing to practice a reliable method of contraception for the duration of the study 11. In good general health at the time of screening (Investigator discretion). 12. Able to read and understand English 13. Able to read, understand, and provide informed consent 14. Able to use a personal smartphone device and download Chloe by PeopleScience, Oura, and MIR Spirobank 15. Able to receive shipment of the product at an address within the United States 16. Able to complete study assessments over the course of up to 6 weeks. Exclusion Criteria: 1. Do not have a personal smartphone, internet access, or are unwilling to download Chloe, Oura, or MIR Spirobank apps 2. Daily/preventative inhaler use 3. Injury, illness, or poor training compliance in the previous 6 months 4. History of COPD, long COVID, fibromyalgia, chronic fatigue syndrome, Lyme disease, or major cardiac or respiratory conditions 5. Lack of access to indoor trainer with power meter 6. High alcohol use or ongoing recreational drug/tobacco use 7. Pregnant, planning to become pregnant during the study, or lactating 8. Use of medications to treat hypertension (high blood pressure) including diuretics, Angiotensin Converting Enzyme inhibitors, Angiotensin II Receptor Blockers, calcium channel blockers, beta blockers, alpha blockers, and other classes used for blood pressure control 9. Any underlying medical conditions or comorbidities that may confound the assessment or the evaluation of the study outcomes. 10. Have a significant illness, disease, or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes. 11. Known hypersensitivity or previous allergic reaction to sodium bicarbonate, citrate, theobromine, arginine, forskolin, maltodextrin, modified food starch, or lactose 12. Are unlikely for any reason to be able to comply with the trial or are considered unsuited for participation in the study by the Principal Investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy normal athletes are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
People Science, Inc.
Los Angeles, California, 90034, United States